The treatment landscape for early-stage non-small cell lung cancer (NSCLC) has seen an exciting shift with recent advances in immunotherapy. With these advances, there is a need for management of common immune-related adverse events (irAEs). Join this expert discussion on the current guidelines and multidisciplinary strategies for monitoring and management of irAEs in patients with early-stage NSCLC.
- Provider:PRIME Education, Inc. (PRIME®)
- Activity Link: https://primeinc.org/online/advancing-care-patients-early-stage-nsclc-management-immune-related-adverse
- Start Date: 2024-02-29 06:00:00
- End Date: 2024-02-29 06:00:00
- Credit Details: IPCE Credits: 0.25 hours
AAPA Category 1 Credit™️: 0.25 hours
AMA PRA Category 1 Credit™️: 0.25 hours
Nursing: 0.25 hours
Pharmacy: 0.25 hours - Commercial Support: Source: Bristol-Myers Squibb Company - Amount: 33166.67 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner Knowledge, Learner/Team Competence
- Provider Ship: Directly Provided
- Registration: Open to all
Subscribe
Login
0 Comments
Oldest